PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas

OBJECTIVE: The BRAF inhibitor, vemurafenib, has been widely used in the treatment of patients with melanoma-bearing BRAF(V600E) mutations. While the initial response to vemurafenib is usually excellent, the majority of patients eventually develop resistance and metastatic disease. However, the under...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Junling, Yang, Jilong, Sang, Lei, Sun, Rui, Bai, Weiyu, Wang, Chao, Sun, Yan, Sun, Jianwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425182/
https://www.ncbi.nlm.nih.gov/pubmed/34570440
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425182/
https://www.ncbi.nlm.nih.gov/pubmed/34570440
http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0294

Ejemplares similares